arrow_back Back to App

Support for New Drugs Against Resistant Infections: The PASTEUR Act

The PASTEUR Act aims to accelerate the development of new drugs to combat dangerous, drug-resistant infections. Through special contracts and funding, pharmaceutical companies will be incentivized to develop innovative antimicrobials, potentially improving access to effective treatments for citizens and enhancing national health security. Additionally, the act supports monitoring drug resistance and educating on proper drug use.
Key points
New Drug Development: A special program will be established to support the development of innovative antimicrobials for the most threatening infections, including those resistant to current treatments.
Research Funding: Companies developing these drugs can expect long-term financial contracts, reducing investment risk and accelerating the availability of new therapies.
Appropriate Drug Use: The act promotes education on the proper use of antimicrobials and monitoring of resistance to ensure drugs remain effective for as long as possible.
Improved Health Security: These measures aim to protect citizens from the growing threat of infections for which effective treatments are lacking.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_2940
Sponsor: Rep. Ferguson, A. Drew, IV [R-GA-3]
Process start date: 2023-04-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PASTEUR Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_2940.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-04-27.

What are the main provisions?

Key points include:

  • New Drug Development: A special program will be established to support the development of innovative antimicrobials for the most threatening infections, including those resistant to current treatments.
  • Research Funding: Companies developing these drugs can expect long-term financial contracts, reducing investment risk and accelerating the availability of new therapies.
  • Appropriate Drug Use: The act promotes education on the proper use of antimicrobials and monitoring of resistance to ensure drugs remain effective for as long as possible.
  • Improved Health Security: These measures aim to protect citizens from the growing threat of infections for which effective treatments are lacking.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Ferguson, A. Drew, IV [R-GA-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health